MedTrace Logo

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

NCT00512785 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 435

Last updated 2012-06-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety and efficacy of imidafenacin.

Conditions

Interventions

DRUG

imidafenacin, KRP-197/ONO-8025

0.1 mg BID for 52 weeks

DRUG

imidafenacin, KRP-197/ONO-8025

0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks

Sponsors & Collaborators

  • Kyorin Pharmaceutical Co.,Ltd

    collaborator INDUSTRY

  • Ono Pharmaceutical Co. Ltd

    lead INDUSTRY

Principal Investigators

  • Yoshifumi Hirahara · Kyorin Pharmaceutical Co.,Ltd

  • Toshihiko Konomi · Ono Pharmaceutical Co. Ltd

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-05-31

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00512785 on ClinicalTrials.gov